Review



cd47  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 93
      Buy from Supplier

    Structured Review

    R&D Systems cd47
    Cd47, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 48 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd47/product/R&D Systems
    Average 93 stars, based on 48 article reviews
    cd47 - by Bioz Stars, 2026-03
    93/100 stars

    Images



    Similar Products

    human cd47 antibody  (Bio-Techne corporation)
    99
    Bio-Techne corporation human cd47 antibody
    Human Cd47 Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human cd47 antibody/product/Bio-Techne corporation
    Average 99 stars, based on 1 article reviews
    human cd47 antibody - by Bioz Stars, 2026-03
    99/100 stars
    		  Buy from Supplier
    cd47  (R&D Systems)
    93
    R&D Systems cd47
    Cd47, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd47/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    cd47 - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier
    anti cd47 polyclonal antibody  (R&D Systems)
    93
    R&D Systems anti cd47 polyclonal antibody
    Expression of <t>CD47</t> in epithelial ovarian cancer tissues (100×) according to IHC staining. Specimens were stained with anti-CD47 <t>polyclonal</t> antibody. CD47 exhibits a predominantly membranous staining pattern, with no nuclear staining observed. A scale of 0–3 was employed: 0: ≤25% staining, 1: >25–50% positivity, 2: >50–75% positivity, cells showed membranous and/or cytoplasmic expression, 3: intense membranous and/or cytoplasmic expression of at least 75% of the tissue section. (A) CD47 IHC staining score of 0; (B) CD47 IHC staining score of 1; (C) CD47 IHC staining score of 2; (D) CD47 IHC staining score of 3. IHC, immunohistochemical.
    Anti Cd47 Polyclonal Antibody, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti cd47 polyclonal antibody/product/R&D Systems
    Average 93 stars, based on 1 article reviews
    anti cd47 polyclonal antibody - by Bioz Stars, 2026-03
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Expression of CD47 in epithelial ovarian cancer tissues (100×) according to IHC staining. Specimens were stained with anti-CD47 polyclonal antibody. CD47 exhibits a predominantly membranous staining pattern, with no nuclear staining observed. A scale of 0–3 was employed: 0: ≤25% staining, 1: >25–50% positivity, 2: >50–75% positivity, cells showed membranous and/or cytoplasmic expression, 3: intense membranous and/or cytoplasmic expression of at least 75% of the tissue section. (A) CD47 IHC staining score of 0; (B) CD47 IHC staining score of 1; (C) CD47 IHC staining score of 2; (D) CD47 IHC staining score of 3. IHC, immunohistochemical.

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: Expression of CD47 in epithelial ovarian cancer tissues (100×) according to IHC staining. Specimens were stained with anti-CD47 polyclonal antibody. CD47 exhibits a predominantly membranous staining pattern, with no nuclear staining observed. A scale of 0–3 was employed: 0: ≤25% staining, 1: >25–50% positivity, 2: >50–75% positivity, cells showed membranous and/or cytoplasmic expression, 3: intense membranous and/or cytoplasmic expression of at least 75% of the tissue section. (A) CD47 IHC staining score of 0; (B) CD47 IHC staining score of 1; (C) CD47 IHC staining score of 2; (D) CD47 IHC staining score of 3. IHC, immunohistochemical.

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing, Immunohistochemistry, Staining, Immunohistochemical staining

    Patient characteristics by pre-NACT CD47 expression

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: Patient characteristics by pre-NACT CD47 expression

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques:

    Expression of CD47 in epithelial ovarian cancer tissues

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: Expression of CD47 in epithelial ovarian cancer tissues

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing, Immunohistochemistry

    Change of CD47 expression pre- and post-NACT. NACT, neoadjuvant chemotherapy.

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: Change of CD47 expression pre- and post-NACT. NACT, neoadjuvant chemotherapy.

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing

    Wilcoxon signed ranks test of the CD47 expression pre- and post-NACT

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: Wilcoxon signed ranks test of the CD47 expression pre- and post-NACT

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing

    Kaplan-Meier curves of CD47 expression for OS and PFS. The figure shows the Kaplan-Meier curves of OS and PFS for CD47 high and low expression in the cohort of 74 patients with EOC who received neoadjuvant chemotherapy, and four cases of stage I and II ovarian cancer were excluded from the analysis. EOC, epithelial ovarian cancer; OS, overall survival; PFS, progression-free survival; NACT, neoadjuvant chemotherapy.

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: Kaplan-Meier curves of CD47 expression for OS and PFS. The figure shows the Kaplan-Meier curves of OS and PFS for CD47 high and low expression in the cohort of 74 patients with EOC who received neoadjuvant chemotherapy, and four cases of stage I and II ovarian cancer were excluded from the analysis. EOC, epithelial ovarian cancer; OS, overall survival; PFS, progression-free survival; NACT, neoadjuvant chemotherapy.

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing

    Multivariate prognostic analysis

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: Multivariate prognostic analysis

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing

    The expression of CD47 mRNA in ovarian epithelial cells (HOSE) and ovarian cancer cells (SKOV3 and ES2) according to RT-qPCR analysis of CD47 mRNA levels. The levels of CD47 mRNA expression in ES2 and SKOV3 cells were found to be significantly higher than those in HOSE cells (P<0.001). ***, P<0.001. RT-qPCR, reverse transcription quantitative polymerase chain reaction; mRNA, messenger RNA; HOSE, human ovarian surface epithelial cell.

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: The expression of CD47 mRNA in ovarian epithelial cells (HOSE) and ovarian cancer cells (SKOV3 and ES2) according to RT-qPCR analysis of CD47 mRNA levels. The levels of CD47 mRNA expression in ES2 and SKOV3 cells were found to be significantly higher than those in HOSE cells (P<0.001). ***, P<0.001. RT-qPCR, reverse transcription quantitative polymerase chain reaction; mRNA, messenger RNA; HOSE, human ovarian surface epithelial cell.

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing, Quantitative RT-PCR, Reverse Transcription, Real-time Polymerase Chain Reaction

    The CD47 mRNA expression in SKOV3 and ES2 cells both with and without cisplatin treatment. A control group was treated with 0 µM of cisplatin, while a second group was treated with 4 µM of cisplatin for 48 hours to assess the expression of CD47 mRNA. (A) The expression of CD47 mRNA in SKOV3 treated with 0 and 4 µM cisplatin for 48 hours. Following 48 hours of treatment with 4 µM of cisplatin, a notable elevation in CD47 mRNA was observed (P<0.001). (B) The expression of CD47 mRNA in ES2 treated with 0 and 4 µM of cisplatin for 48 hours. Following a 48-hour treatment with 4 µM of cisplatin, a notable elevation in CD47 mRNA was evident (P<0.001). ***, P<0.001. mRNA, messenger RNA; DDP, cisplatin.

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: The CD47 mRNA expression in SKOV3 and ES2 cells both with and without cisplatin treatment. A control group was treated with 0 µM of cisplatin, while a second group was treated with 4 µM of cisplatin for 48 hours to assess the expression of CD47 mRNA. (A) The expression of CD47 mRNA in SKOV3 treated with 0 and 4 µM cisplatin for 48 hours. Following 48 hours of treatment with 4 µM of cisplatin, a notable elevation in CD47 mRNA was observed (P<0.001). (B) The expression of CD47 mRNA in ES2 treated with 0 and 4 µM of cisplatin for 48 hours. Following a 48-hour treatment with 4 µM of cisplatin, a notable elevation in CD47 mRNA was evident (P<0.001). ***, P<0.001. mRNA, messenger RNA; DDP, cisplatin.

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing, Control

    Expression of cell surface CD47 protein in SKOV3 and ES2 cells following cisplatin treatment. (A) Following a 48-hour cisplatin treatment period, the mean fluorescence intensity of the surface CD47 protein in SKOV3 cells demonstrated a statistically significant increase (P<0.001). (B) Following a 48-hour cisplatin treatment period, the mean fluorescence intensity of the surface CD47 protein in ES2 cells demonstrated a notable increase (P<0.001).

    Journal: Gland Surgery

    Article Title: Chemotherapy-induced increase in CD47 expression in epithelial ovarian cancer

    doi: 10.21037/gs-24-400

    Figure Lengend Snippet: Expression of cell surface CD47 protein in SKOV3 and ES2 cells following cisplatin treatment. (A) Following a 48-hour cisplatin treatment period, the mean fluorescence intensity of the surface CD47 protein in SKOV3 cells demonstrated a statistically significant increase (P<0.001). (B) Following a 48-hour cisplatin treatment period, the mean fluorescence intensity of the surface CD47 protein in ES2 cells demonstrated a notable increase (P<0.001).

    Article Snippet: Anti-CD47 polyclonal antibody (cat. no. AF4670; R&D Systems, Minneapolis, MN, USA) was added at a dilution of 1:150 to each section and incubated overnight at 4 ℃ ( ).

    Techniques: Expressing, Fluorescence